Peptide receptor radionuclide therapy
- 1 March 2007
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 21 (1), 111-129
- https://doi.org/10.1016/j.beem.2007.01.007
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- 213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal ModelClinical Cancer Research, 2006
- Endocrine tumours of the pancreasBest Practice & Research Clinical Gastroenterology, 2005
- Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner TumorenDer Onkologe, 2004
- Quality of Life in Patients With Gastroenteropancreatic Tumors Treated With [177Lu-DOTA0,Tyr3]octreotateJournal of Clinical Oncology, 2004
- Assessment of Hepatic Toxicity from Treatment with 90Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver MetastasesCancer Biotherapy & Radiopharmaceuticals, 2003
- Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsSeminars in Nuclear Medicine, 2002
- DOTATOC: A powerful new tool for receptor-mediated radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- Cloning, Functional Expression and Pharmacological Characterization of a Fourth (hSSTR4) and a Fifth (hSSTR5) Human Somatostatin Receptor SubtypeBiochemical and Biophysical Research Communications, 1993
- Somatostatin Receptors: Orphan That Found Family and FunctionMolecular and Cellular Neuroscience, 1993
- The stability in liver homogenates of indium-111 and yttrium-90 attached to antibody via two popular chelatorsNuclear Medicine and Biology, 1993